# healthyn

VOLUME 6 | NUMBER 5 | SEPT./OCT. 2011

www.mvphealthcare.com

### IN THIS ISSUE

MVP Launches New Call Menu	2
Medical Policy Updates	3
Web Updates	4
Pharmacy Updates	
UM Updates	
Clinical Guidelines Re-approved	7
Caring for Your Older Patients	7

### New electronic claim submission rules begin January 1, 2012

If you currently submit electronic claims using an ANSI X12 4010 A1 837-P or 837-I format to MVP Health Care, you must switch to an ANSI X12 5010 837-P or 837-I format by January 1, 2012. MVP is already prepared to accept 5010 837-P and 837-I electronic claim submissions.

- If you submit electronic claims directly to MVP, you may contact MVP's EDI Services Department at 1-877-461-4911 to schedule a test of an ANSI X12 5010 837-P or 837-I file. Once a successful test has been completed, EDI Services will schedule your production implementation of 5010 837-P or 837-I claim submissions, which may be prior to January 1, 2012.
- If you currently submit claims to a clearing house, which in turn sends an electronic claim file to MVP, please work with your clearing house to ensure the data you submit will allow the clearing house to send MVP a compliant 5010 837 file.

If you submit a 4010 837-P or 837-I electronic claim file to MVP on or after January 1, 2012, your claim file will be rejected as non-compliant.

Electronic claims experience is an average of 12-15 days faster than paper submissions due to the manual intervention required for paper claims. Please also be aware that rejections for electronically-submitted claims are within 24 hours versus 5 days to receive notice for paper submissions and additional time to resubmit then.

### Upcoming updates to MVP ID cards

MVP Health Care recently selected a new vendor partner to facilitate the printing and distribution of ID cards. We are taking this opportunity to update the design and content of all the ID cards we produce to make it easier for health care providers and members to find the information on the cards that pertains to them.

• Updates include a more standardized set of informational

### David W. Oliker



MVP President & Chief Executive Officer Healthy Practices is a bi-monthly publication of the Corporate Affairs Dept.

components on the ID cards. By making the content more consistent, we can streamline the ID card production process. better ensure card accuracy and reduce language variations that may cause confusion for provider offices.

**ractices** 

- Commercial members with a copay/coinsurance cost share will now see "Urgent Care" called out on the front of the card to highlight the cost savings of using urgent care instead of the emergency room when appropriate.
- ID cards for Medicare members have a cleaner look that is easier to read. We paid special attention to making the member ID number as large as possible. Plus, Medicare members with Part D prescription drug coverage will now need only one card for all of their services!
- Information on the back is grouped by audience so that health care providers, pharmacists and members can easily find the information they need on the card.

The updated ID cards will be distributed to Commercial and Medicaid members gradually beginning this fall, as members require or request new cards due to plan changes and regulatory requirements. Medicare members will receive new cards in November and December.

Please be aware that as MVP phases out the current card design, you will see patients with both the "old" and "new" card design. Both are valid for Commercial members. Medicare members' cards will activate automatically on Jan. 1, 2012 for all members. Just remember to log in at www.mvphealthcare.com/ **provider** to check each patient's eligibility and ask to see the most current copy of the member's card at every visit.

Samples of the new cards are on the following page.

### **Potential HIPAA issues when submitting EOB/EOP** to support payment of claims

There are times when MVP requires providers to submit claims with an Explanation of Benefits (EOB) or Explanation of Payment (EOP) to process a claim. MVP recently noticed that providers are submitting EOB/EOPs for MVP members with other members' protected health information still visible. This may be considered a HIPAA violation, so we are asking for your cooperation in maintaining the protected health information of your patients and our members.


Please be advised when you submit a claim to MVP with an EOB/EOP as an attachment that you need to suppress or black out all other information that does not pertain to the member about which you are inquiring. This will ensure that providers and MVP are keeping our members' protected health information secure and safe. Thank you for your assistance.

### **Contacting Professional Relations**

MVP Corp. Headquarters	(888) 363-9485	
Southern Tier	(607) 651-9141	
Central New York	(800) 888-9635	
Midstate	(800) 568-3668	
Mid-Hudson	(800) 666-1762	

Comments

Write to: Healthy Practices MVP Health Care, Inc., Professional Relations Dept. PO Box 2207, Schenectady, NY 12301



# Coming September 21: MVP launches new call menu, voice options

MVP is moving toward enabling fast, simple self-service capabilities for the health care providers and members who call MVP. We will upgrade our phone system in two phases.

The first phase, which will launch on the evening of Wednesday, September 21, will enable callers to speak their choices to navigate our phone menu or connect with a live representative. This Interactive Voice Response (IVR) system is a "smarter" system both for our callers and for our staff, who will gain call handling features that will allow us to better serve your needs.

### Which phone numbers will be upgraded

Your practice should be aware that the following phone numbers are part of the IVR phone system upgrade:

Customer Care Center

for Provider Services:	1-800-684-9286
Utilization Management:	1-800-568-0458

MVP also is upgrading many of its Customer Care Center phone lines called by our members.

### New menu options

As part of the IVR phone system upgrade, MVP is adopting a more streamlined phone option menu, allowing the IVR system to recognize spoken preferences and route calls where they need to go.

To help you prepare for the addition of the speech-enabled IVR, the main menu options will include eligibility, benefits, authorizations, claims, and other, with appropriate sub-menus in place to serve your more specific needs. While the new menu is easy to navigate even if you don't know the options before you call, you can speak your preferences if you know them and speed through the call routing process. Touch tone options will continue to be available.

### Self-service features coming in 2012

Enhancing the IVR system enables the second phase of MVP's phone system upgrade, which will launch in 2012 and include greater self-service functionality that will give members and health care providers the opportunity to obtain information on more routine inquiries, without waiting to speak with a live representative. We will share more information about these features as it becomes available!

# **Professional Relations Updates**

### Fee integration updates

For claims with a date of service on or after January 1, 2012, MVP will be changing the way particular modifiers/codes are reimbursed. This is a result of a continued effort to integrate pricing practices across the MVP enterprise.

### Please review the following information for more detail: Anesthesia Modifier Codes QK, QX and QY

Modifier codes QK, QX or QY will be reimbursed at 50% of the reimbursable amount. This applies to professional claims only for all lines of business.

The following is supporting documentation from the CMS Anesthesia Billing Guide:

### **Payment Rules**

The fee schedule allowance for anesthesia services is based on a calculation that includes the anesthesia base units assigned to each anesthesia code, the anesthesia time involved, and appropriate area conversion factor. The following formulas are used to determine payment:

### CRNA Medically Directed (Modifier QX)

(Base Units + Time Units) x Participating Conversion Factor = Allowance x 50%

Participating Physician Medically Directing (Modifier QY, QK)

(Base Units + Time Units) x Participating Conversion Factor = Allowance x 50%

# • Non-Participating Physician Medically Directing (Modifier QY, QK)

(Base Units + Time Units) x Non-Participating Conversion Factor = Allowance x 50%

### Unpriced codes less than \$50

These codes were previously reimbursed at 80% of charges and will now be reimbursed at 100% of charges.

**GAP code pricing** – MVP will no longer use Ingenix for gap pricing. Reimbursement will be based on a percentage of reasonable charges.

### Modifiers

**Modifier 52 (Reduced Services)** – Will be reimbursed at the lesser of 50% of charges or contracted rate

**Modifier 55 (Post Operative Management Only)** – Will be reimbursed at the lesser of 10% of charges or contracted rate

Modifier 56 (Pre Operative Management Only) – Will be reimbursed at the lesser of 10% of charges or contracted rate

**Modifier 78 (Unplanned return to ER, post-op)** – Will be reimbursed at the lesser of 80% of charges or contracted rate.

# **Medical Policy Updates**

The MVP Quality Improvement Committee (QIC) approved the policies summarized below during the April, June, and July meetings. Some of the medical policies may reflect new technology while others clarify existing benefits. All policy updates are listed online in the *Benefits Interpretation Manual* (BIM). Visit MVP online at **www.mvphealthcare.com**. Providers can directly access the online BIM through the Reference section of the Provider portal. The *Current Updates* page of the BIM lists all medical policy updates. If you have questions regarding the medical policies or wish to obtain a paper copy of a policy, contact your Professional Relations representative.

Healthy Practices and/or FastFax will continue to inform your office about new and updated medical policies. MVP encourages your office to look at all of the revisions and updates on a regular basis in the *Benefit Interpretation Manual* (BIM) located on **www.mvphealthcare.com** in the *Reference* section.

### Imaging policy updates effective August 1, 2011

MVP utilizes InterQual<sup>®</sup> criteria for many imaging procedures. (see *UM Updates InterQual<sup>®</sup> Reminder* in this newsletter). The updated 2011 InterQual<sup>®</sup> criteria were previously made available to providers via the MVP provider Web site. The following imaging policies may reflect InterQual<sup>®</sup> criteria updates, if applicable, effective August 1, 2011.

### MRA Brain

Pre-operative study, carotid endareterectomy planned has been deleted as an indication.

### **MRA** Carotid

There are no changes to this policy.

### MRA Kidney

There are no changes to this policy.

### **MRA Lower Extremity**

Peripheral aneurysm by PE/duplex US and angiography not planned has been added as an indication.

### **MRI Abdomen**

There are no changes to this policy.

### **MRI Chest**

For cardiac indications, suspected intracardiac mass "by transthoracic echocardiogram" was added.

### MRI Extremity

There are no changes to this policy.

### MRI Hip/Knee

There are no changes to this policy.

### **MRI Neck**

There are no changes to this policy.

### **MRI** Pituitary

There are no changes to this policy.

### MRI Shoulder/Wrist

There are no changes to this policy.

### PET Scan Chest/Cardiac

The policy follows InterQual criteria and contains a Medicare Variation. There are no changes to the policy.

### PET Scan Whole Body

This policy was updated to reflect the most recent InterQual indications for PET Whole Body. Multiple myeloma, testicular cancer and baseline part of staging, soft tissue sarcoma and baseline part of staging, and ovarian cancer have been added as indications. The Medicare Variation section was updated to include bone metastasis for cancer. NaF-18 PET imaging is covered Bone Metastasis for Cancer when the member is enrolled in a clinical registry.

### Medical policy updates effective October 1, 2011

### **Continuous Passive Motion Device**

Coverage for continuous passive motion device is limited to procedures for the treatment of the knee. Continuous passive motion devices are not covered for the shoulder or elbow.

### **CT** Coronary Arterial Disease

There are no changes to this policy.

### Endovascular Procedures

The policy has been updated to reflect that endovascular repair for abdominal aortic aneurysm is covered for patients with a documented unruptured abdominal aortic aneurysm who meet the medical policy criteria. The requirement for patients who are not candidates for open surgical repair has been removed.

### **Evaluation of New Technology**

The policy addresses the process for evaluating new technology or services. There are no changes to this policy.

### High Frequency Chest Wall Oscillation Devices

There are no changes to this policy.

### **Home Care Services**

There are no changes to this policy.

### Low Vision Aids

The policy has been updated to reflect that due to the lack of data in peer reviewed literature, low vision aids are considered not medically necessary. An Option, Option Family, Option Child Variation has been added that low vision aid services will be considered when criteria are met.

### Metal-on-Metal Hip Resurfacing

There are no changes to this policy.

### Obstructive Sleep Apnea – Diagnosis (NY) NEW POLICY

The policy addresses obstructive sleep apnea diagnosis criteria

for New York State. The Exclusion criteria section has been updated to list diagnoses and conditions not indicated for polysomnography. Home sleep studies are not covered, except for Medicare products.

### **Obstructive Sleep Apnea - Diagnosis ARCHIVED POLICY**

This policy is archived as there are now two new Obstructive Sleep Apnea-Diagnosis policies. Please refer to Obstructive Sleep Apnea – Diagnosis (NY) and Obstructive Sleep Apnea – Diagnosis (Vermont and New Hampshire).

### **Obstructive Sleep Apnea - Devices**

Auto-titrating positive airway pressure (APAP) language was added to the policy. A Medicare Variation for oral appliances was added to the policy. Oral appliances for obstructive sleep apnea are covered when policy criteria are met.

Please refer to the coding section on the policies to identify any code changes (e.g., new, deleted) or codes no longer requiring prior authorization for a specific policy. Each policy grid defines the prior authorization requirements for a specific product.

### **Radiopharmaceutical policy**

Beginning January 1, 2012, MVP will be changing our Radiopharmaceutical Policy as follows:

Any Radiopharmaceutical Codes that are billed  $less \, than\, \$50$  will be reimbursed at 100% of charges per standard MVP policy.

The following Radiopharm codes will be paid at 100% of charges up to \$100 dollars:

### • A9541 • A9560

The following Radiopharm codes will be paid at 100% of charges up to \$160 dollars:

- A9500 A9538
- A9502 A9552
- A9505

The following Radiopharm codes will be paid at 100% of charges up to \$250 dollars:

### • A9562 • A9556

Any other Radiopharm codes or any Radiopharm codes that do not meet the criteria above will require an invoice.

This policy applies to physician claims only, for all lines of business except Medicare.

# **Web Updates**

### Provider portal enhancement: benefits display

*Benefits Display* offers users of MVP's Web portals quick and comprehensive access to benefit information, improving users' ability to self-serve.

In January, 2011, *Benefits Display* became available to Web portal users — members, employers, brokers and health care providers — to allow access to benefit information for members of select Facets-based products (the Federal Government plan, the New York State Health Insurance Plan [NYSHIP], the Finger Lakes Consortium and Medicare).

By the end of 2011, nearly all members' Facets-based health plans will be linked to a *Benefits Display*, offering an enhanced view of your patients' coverage and payment responsibilities.

To access the *Benefits Display* for a patient, log in at **www.mvphealthcare.com/provider**, perform a patient inquiry and select a patient, then go to *Patient Information*. If the patient search is for a member whose health plan is configured for *Benefits Display*, the patient's health plan name in the *Subscriber and Policy Details* section will be underlined and blue – a hotlink that will bring up the *Benefits Display*.

We think that your practice will find the *Benefits Display* a valuable addition to MVP's Web portal for providers; we are pleased to make this feature more widely available by year-end!

### **Disabling default provider portal accounts**

In the last issue of *Healthy Practices*, we announced that, to ensure the highest level of security for our Web portal users, as of July 5, 2011 we would no longer allow provider portal login usernames to be the same as provider IDs and would disable any accounts with matching usernames/provider IDs.

Based on your feedback, we have extended the timeframe during which portal users may complete the necessary steps to ensure that every user in your practice has a unique login. Accounts with matching usernames/provider IDs will not be disabled until October 1, 2011.

If your MVP provider Web portal username contains part or all of your last name, no action is required. If, however, your MVP provider Web portal username is the same as your practice's MVP payee ID, please follow these action steps to retain your access to the provider portal after October 1:

- 1. Designate a site administrator through MVP's online portal registration process (www.mvphealthcare.com/provider/ register.html)
- 2. Request usernames and passwords for staff, also through the online registration process.

Please note that staff usernames and passwords cannot be set up without the site administrator request form or without an existing site administrator.

If you have any questions, please contact MVP eSupport (esupport@mvphealthcare.com or 1-888-656-5695).

### Not yet registered for an online account?

By registering for an account at **mvphealthcare.com** allows you a fast, easy way to get information you need about your MVP patients, our policies and procedures, newsletters and much more. If your practice has Internet access, visit **www.mvphealthcare.com/provider/register.html** to set up accounts for your staff. New features are constantly in development to make your online account a valuable tool for your practice!

### Update your provider account profile

If your online account profile includes an outdated or personal e-mail address, take a moment to update it with your current business e-mail address. As MVP continues to explore ways of getting you the information you need via the technology you prefer, your valid e-mail address and profile information will enable you to quickly and easily be part of our advancements! You can update your e-mail address, password and security question at any time by clicking the *Change Profile* link (under your name) just after logging in at **www.mvphealthcare.com/provider.** 

# **Pharmacy Updates**

### Pharmacy policy and formulary updates

### **Enteral Therapy**

Effective October 1, 2011 for non-Medicare members, enteral nutrition must be obtained at an MVP participating pharmacy and adjudicate through the MVP pharmacy benefits manager (PBM). Copays and/or coinsurances are subject to the member's enteral product benefit. Home infusion vendors that also participate with MVP as a pharmacy provider must bill using a valid NDC/UPC product number. Enteral products indicated for inherited diseases of metabolism (ie: PKU, MSUD) will adjudicate without prior authorization. All other products require prior authorization to determine medical necessity as established in MVP policy.

### Tamiflu Dosing Change

When flu season arrives this fall, a liquid form of Tamiflu will be available in a new, lower concentration to reduce the possibility of medication errors. The change applies to the oral suspension form of Tamiflu and not the capsule. The Tamiflu packaging of its oral suspension product says "new strength" because the concentration of medicine in the liquid has been changed from 12 mg/mL to 6 mg/mL. This change in concentration means that the amount of medicine that must be taken has also changed.

### **Effective September 1, 2011**

### Advanced Agents for Pulmonary Arterial Hypertension

- Indications for Adcirca and Flolan were updated
- Exclusion section updated to indicate Letairis is contraindicated in pregnancy

### **Contraceptive Agents and Family Planning**

• Lo Seasonique was added to the policy

### **Cystic Fibrosis**

- Cayston was added to the policy
- Criteria for extension of therapy was added

### Gaucher's Disease

Vpriv was added to the policy

### Infertility

- Fertinex was removed from the policy as it is no longer on the market
- Follistim AQ is preferred over Gonal-F
- Specific lab documentation criteria was added

### Intranasal Corticosteroids

• Nasarel was removed from the policy as it is no longer on the market

### Multiple Sclerosis, Select Oral Agents

- Name changed from Ampyra
- Gilenya and Ampyra criteria are similar

### **Orphan Drugs**

• Soliris and Lumizyme were added to the policy

### Effective October 1, 2011

### ACE/ARB

- Prior authorization will be required for Azor, Tribenzor and Twynsta
- Option and Option Family variation was added. Losartan/HCTZ and Diovan/HCT are the preferred ARBs for these products

### Acthar

• New indication for infantile spasms was added

### Androgens/Anabolic Steroids

• This is a new policy for MVP Option and MVP Option Family members only. Prior authorization is required and is limited to FDA approved indications only

### Antineoplastic Enzyme Inhibitors

• MVP Option and MVP Option Family variation was added that require prior authorization for Gleevec. Established criteria in the policy applies

### **Direct Renin Inhibitors**

• Tekamlo and Amturnide were added to the policy

### **Enteral Therapy New York**

 MVP Option and MVP Option Family variation was added. In addition to criteria established in the policy, these members would also need to be fed via nasogastric, gastrostomy or jejunostomy tube

### Gout

• New policy requiring quantity limits of 60/30 for Colcrys and step therapy or prior authorization for Uloric and Krystexxa

### **Growth Hormone**

• Option and Option Family variation was added. Tev-Tropin and Humatrope are the preferred growth hormones for these products

### Mail Service

• Pradaxa was added as excluded from mail order

### **Proton Pump Inhibitors**

• MVP Option and MVP Option Family variation was added. Generic PPIs are preferred for these products

### **Quantity Limits**

• MVP Option and MVP Option Family variation was added. Subutex, Suboxone and generic equivalents are limited to 60 units per 30 days

## The following policies were reviewed and approved without any changes to criteria:

- Acromegaly
- Fabry's Disease
- Hereditary Angioedema
- Kuvan
- Leukotriene Modifiers
- RSV
- Samsca
- Smoking Cessation Medications
- Xolair
- Zorbtive

### Formulary updates for Commercial members

The MVP formulary is updated after each Pharmacy and Therapeutics Committee meeting. The most current version is available online at **www.mvphealthcare.com**. Simply visit the site's *Provider* section and under *Pharmacy*, click on *Formulary*. The MVP Formulary can be downloaded to a PDA device from **www.epocrates.com**. There is a link to ePocrates<sup>®</sup> on the MVP Web site

## New drugs<sup>†</sup> (recently approved by the FDA, prior authorization required, Tier 3)

Drug Name	Indication
Axiron	Testosterone deficiency
Benlysta <sup>†</sup> (medical)	Systemic lupus erythematosus
Banzel susp	Lennox-Gastaut syndrome
Butrans	Moderate-to-severe chronic pain
Corifact <sup>†</sup> (medical)	Factor XIII deficiency
Daliresp	COPD
Dificid	Diarrhea caused by c.difficile
Edarbi	Hypertension
Edurant	HIV-1 infection
Horizant	Restless leg syndrome
Incivik+	Chronic hepatitis C
Krystexxa† (medical)	Gout
Lastacaft	Allergic conjunctivitis
Nexiclon XR	Hypertension
Nulojix	Prophylaxis for organ rejection
Phoslyra	Reduction of serum phosphorus
Rezira	Cough and cold
Staxyn	Erectile dysfunction
Sylatron	Melanoma
Tradjenta	Type 2 diabetes mellitus
Victrelis+	Chronic hepatitis C
Viramune XR	HIV-1 infection
Xerese	Treatment and prevention of cold sores
Yervoy <sup>†</sup> (medical)	Metastatic melanoma
Zictifa	Thyroid cancer
Zutripto	Cough and cold
Zytiga+	Prostate cancer
Generic drugs added to F	ormulary (Tier 1)
budesonide oral	fondaparinux
carbamazepine 12 hour	londaparniax
(generic Carbatrol)	triamcinolone nasal
epinastine	levofloxacin
letrozole	Loryna (generic Yaz)
methylphenidate	Loryna (genene Taz)
(generic Concerta)	cyclobenzaprine (generic Amrix)
and drugs added to Forr	nulary (Tier 2) Nitrostat
Follictim AO	
Follistim AQ Pulmicort Respules	Ventolin HFA

AtelviaKombiglyze ERBeyazLatudaBromdayLo Loestrin FEEgriftaNuedextaHalaven†SuprepIprivaskTeflaro†KapvayKapvay

### Drugs removed from the Formulary\* (change from Tier 2 to Tier 3):

- Carbatrol
- Concerta
- Femara
- Proventil HFA (effective 9/1/2011)
- \*Affected members will receive a letter if further action is required (i.e. contacting the prescriber for a formulary alternative)

<sup>†</sup>Drugs indicated as "medical", when provided in a physician office or outpatient facility, are a covered Medicare Part B benefit and are subject to MVP commercial policies.

- <sup>sT</sup>Subject to step therapy
- <sup>QL</sup>Subject to quantity limits
- +Curascript mandatory

### **Medication recalls and withdrawals**

In the past several weeks, the Food and Drug Administration (FDA) has issued important medication warning, withdrawals and recalls. Highlights of the FDA activity include:

- In June, Endo Pharmaceutical announced a nationwide consumer recall of Endocet because some bottles may contain different strengths. MVP has notified 163 members who might have been impacted by this recall.
- In June, Qualitest announced a recall of specific lots of butalbital/APAP/caffeine and hydrocodone/APAP due to the possibility that the bottles may contain incorrect tablets. MVP has notified 61 members who might have been impacted by this recall.

# **UM Updates**

### DMEPOS provider auditing program underway

Effective September 1, 2011, MVP Health Care's DME Utilization Management Unit will begin conducting audits of durable medical equipment (DMEPOS) claims.

The purpose of these audits is to:

- substantiate claims for medical necessity, appropriate coverage/applicable benefits and justification of charges;
- identify adverse utilization trends;
- · identify inappropriate claims submission; and
- assess aberrant billing methods that affect copayments for MVP members.

The DME audits will be conducted for HCPCS codes billed to MVP that are not included on the DME Prior Authorization Code List. Action(s) resulting from the audits may include further investigation, possible claim adjustments, feedback to vendors and provider education.

If you have questions about the auditing program, please contact Dan Flanagan, DME Supervisor, at **518-388-2281**.

# Effective January 1: new clinical editing knowledge pack

MVP Health Care will enhance its clinical editing application, McKesson<sup>®</sup> ClaimsXten<sup>™</sup>, an industry-recognized software program, with a new **Waste and Abuse Knowledge Pack** on January 1, 2012. McKesson ClaimsXten ensures that payment policies are applied consistently while providing additional transparency for providers.

The sources of ClaimsXten's correct coding standards include but are not limited to:

- National Correct Coding Initiative (NCCI)
- American Medical Association (AMA)
- Current Procedural Terminology (CPT®)
- Healthcare Common Procedure Coding System (HCPCS)

These standards are currently used for facility and non-facility claims.

If you have any questions about these changes, please contact your Professional Relations Representative.

### Reminder: InterQual criteria use began August 1

InterQual<sup>®</sup> criteria, published by McKesson<sup>®</sup> Health Solutions, are used in many of MVP Health Care's medical review processes to support the medical necessity of health care services. The criteria are updated by McKesson Health Solutions to be consistent with evidence-based standards of care and current practices. Please be aware that MVP began using the 2011 InterQual Criteria on August 1, 2011.

To access 2011 InterQual criteria, log in at

### www.mvphealthcare.com/provider.

Questions? Call the Customer Care Center for Provider Services.

### **Vitamin D testing recommendations**

Are you wondering what to tell your patients who are concerned about their Vitamin D level and ask to have it tested?

A November 2010 report from the Institute of Medicine (IOM) entitled *Dietary Reference Intakes for Calcium and Vitamin D* provides sound information on which to base recommendations. This report summarizes the IOM's study of health outcomes compared to Vitamin D and calcium levels. After assessing more than 1,000 studies, the IOM concluded that information about the health benefits tied to these two nutrients were from studies that provided often mixed and inconclusive results and could not be considered reliable. Only bone health was tied to having sufficient levels of Vitamin D and calcium.

### General recommendations based on this report are:

- There is no conclusive evidence supporting routine Vitamin D testing for healthy adults or for children.
- Nearly all Americans obtain sufficient Vitamin D from their diet without supplementation for bone health.
- There are special populations identified as being at risk for Vitamin D deficiency (immigrant populations, those with dark skin, the elderly who are institutionalized or who are obese). Individuals in these groups may benefit from Vitamin D testing and supplementation.

### The Local Coverage Determination for Vitamin D Assay Testing (L29510) indicates that, for Medicare beneficiaries:

- The level of 25-hydroxyvitamin D be measured. Measurement of other metabolites is generally not medically necessary.
- Vitamin D testing may not be used for routine screening.
- Once a beneficiary is shown to be vitamin D deficient, further testing is medically necessary only to ensure adequate replacement has been accomplished. Thereafter, annual testing may be appropriate depending upon the indication and other mitigating factors.

# **Quality Updates**

### **Clinical guidelines re-approved**

MVP's Quality Improvement Committee (QIC) recently re-approved the following existing clinical guidelines:

MVP Health Care, as part of its continuing Quality Improvement Program, has adopted Adult Preventive Care Guidelines. These adult prevention guidelines reflect the most current recommendations of the United States Preventive Services Task Force (USPSTF). For adult immunizations, MVP continues to endorse the current recommendations of the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC).

### **Smoking Cessation:**

MVP continues to endorse the Health and Human Services (HHS) smoking cessation guideline. The HHS recommendations include tips for assessing a patient's readiness to quit and suggested medications for patients who want to stop smoking. Additionally, there is a tear sheet containing tips for patients to improve their chances of quitting successfully.

### Adult Low Back Pain:

MVP's low back pain guideline is from the Institute of Clinical Systems Improvement (ICSI). ICSI is an independent non-profit organization that provides health care quality improvement to medical organizations. A copy of the guideline is available online from ICSI at: www.icsi.org/guidelines\_and\_more/guidelines\_ order\_sets\_protocols/musculo-skeletal/low\_back\_pain/ low\_back\_pain\_\_adult\_5.html. There is an executive summary included along with an easy to follow algorithm. The guideline is 74 pages long, although the first 24 pages are most relevant to MVP's membership. The remaining pages offer annotations that support the specific recommendations of the algorithm.

Paper copies of these recommendations are available by calling MVP's Quality Improvement (QI) department at **1-800-777-4793, ext 2602.** The current edition of the manual online at **www.mvphealthcare.com/provider/qim/index.html.** Offices interested in receiving a paper copy of the updated guidelines should call the QI Department at the number above.

# Caring for Your Older Adult Patients

# CMS Star measures point the way to a 5-star member experience

MVP Health Care now has over 101,000 Medicare members. It is extremely important that we offer benefits to our members that help them "take on life and live well." This includes ensuring that the care received by our members, your patients, continues at a high level of quality, even as the health care system continues to change.

### Continue to emphasize preventive care

We are very fortunate in our service area to have so many good physicians who care for older adult patients. There are many physicians who have already begun transforming their practices into Patient Centered Medical Homes, implementing strategies to draw patients into their offices for preventive care services.

An annual visit is a covered benefit for our Medicare members at no cost to them. This exam will give you the opportunity to assess your patient, to keep them healthy and to identify any problems that may be starting to develop. It is an opportune time to talk about and put in place a plan of care (with input from your patient and his or her representative, when necessary) that identifies the services they should receive throughout the year. As noted in the "Clinical Guidelines Re-Approved" article in this issue, MVP's Adult Preventive Care guidelines contain key USPSTF recommendations in an easy-to-follow table format. There is a special section for people ages 65 and older that includes additional tips, as the recommendations are tailored to this age group. You will see that many of these tips relate to the Stars measures shown below.

### CMS Star program raises the bar

Articles in the last two issues of *Healthy Practices* have introduced the Star program and the expectations that the

Centers for Medicare and Medicaid Services (CMS) has of MVP and the physicians who contract with MVP to care for our Medicare members. CMS is now rating the MVP Preferred Gold HMO and GoldAnywhere PPO products based on clinical outcome measures, member satisfaction (access and service) and administrative oversight. Currently, the list includes 53 measures.

For many of these clinical measures, MVP and our physicians are rated at a 5-star level across our contracts. This is the highest CMS rating (star ratings are 1 – 5). Our current ratings, though, also point out opportunities for improvement in a number of clinical measures, which are listed here.

In the coming months, MVP will be working with physicians and members to improve these results. Please think about ways to improve these results within your own practice. If you are interested in getting further information about these clinical measures or if you have suggestions as to how we might improve, please contact Mary Orr, Associate Director, Medical Quality Management, Government Programs, at **1-585-327-2284** or **morr@mvphealthcare.com**.

CMS Star Program: Cli	nical Measures on which MVP is Focusing for Improvement
CLINICAL MEASURE (SOURCE)	DESCRIPTION
Annual Flu Vaccine (Member survey data)	Percent of plan members aged 65+ who got a vaccine (flu shot) prior to flu season.
Breast Cancer Screening (Claims data)	Percent of female plan members aged 40-69 who had a mammogram during the past 2 years.
Cardiovascular Care – Cholesterol Screening (Claims data)	Percent of plan members with heart disease who have had a test for "bad" (LDL) cholesterol within the past year.
Controlling High Blood Pressure (Medical record review data)	Percent of plan members with high blood pressure who got treatment and were able to maintain a healthy pressure.
Diabetes Care – Kidney Disease Monitoring (Claims & medical record review data)	Percent of diabetic MA enrollees who either had a urine micro-albumin test during the measurement year, or who had received medical attention for nephropathy during the measurement year.
Drug Plan – members 65 and older receive a prescription for certain drugs with a high risk of side effects (CMS & pharmacy claims data)	Percent of Medicare Part D beneficiaries 65 years or older who received at least one prescription for a drug with a high risk of serious side effects in the elderly.
Improving Bladder Control (Member survey data)	Percent of members with a urine leakage problem who discussed the problem with their doctor and got treatment for it within 6 months.
Improving or Maintaining Mental Health (Member survey data)	Percent of all plan members whose mental health was the same or better than expected after two years.
Improving or Maintaining Physical Health (Member survey data)	Percent of all plan members whose physical health was the same or better than expected after two years.
Monitoring Physical Activity (Member survey data)	Percent of senior plan members who discussed exercise with their doctor and were advised to start, increase or maintain their physical activity during the year.
Osteoporosis Management (Claims data)	Percent of female plan members who broke a bone and got screening or treatment for osteoporosis within 6 months.
Reducing the Risk of Falling (Member survey data)	Percent of Medicare members 65 years of age or older who had a fall or had problems with balance or walking in the past 12 months, who were seen by a practitioner in the past 12 months and who received fall risk intervention from their current practitioner.
Rheumatoid Arthritis Management (Claims data)	Percent of plan members with Rheumatoid Arthritis who got 1 or more prescription(s) for an anti-rheumatic drug.
Using the kind of blood pressure medication that is recommended for people with diabetes (CMS & pharmacy claims data)	Percent of Medicare Part D beneficiaries who were dispensed a medication for diabetes and a medication for hypertension who were receiving an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) medication.